BR112023021631A2 - Inibidor, anticorpo ou fragmento de ligação a antígeno, composição farmacêutica, sequência de polinucleotídeo, cassete de expressão, vetor recombinante, célula hospedeira, métodos para preparar o anticorpo ou fragmento de ligação a antígeno e para diagnosticar ou prognosticar uma condição causada pela aglutinação mediada por plaqueta, kit para diagnosticar um indivíduo, e, uso - Google Patents

Inibidor, anticorpo ou fragmento de ligação a antígeno, composição farmacêutica, sequência de polinucleotídeo, cassete de expressão, vetor recombinante, célula hospedeira, métodos para preparar o anticorpo ou fragmento de ligação a antígeno e para diagnosticar ou prognosticar uma condição causada pela aglutinação mediada por plaqueta, kit para diagnosticar um indivíduo, e, uso

Info

Publication number
BR112023021631A2
BR112023021631A2 BR112023021631A BR112023021631A BR112023021631A2 BR 112023021631 A2 BR112023021631 A2 BR 112023021631A2 BR 112023021631 A BR112023021631 A BR 112023021631A BR 112023021631 A BR112023021631 A BR 112023021631A BR 112023021631 A2 BR112023021631 A2 BR 112023021631A2
Authority
BR
Brazil
Prior art keywords
antigen
antibody
binding fragment
diagnosing
mediated
Prior art date
Application number
BR112023021631A
Other languages
English (en)
Portuguese (pt)
Inventor
Alan Lewis
Nadine Clemo
Tom Mckinnon
Original Assignee
Ip2Ipo Innovations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ip2Ipo Innovations Ltd filed Critical Ip2Ipo Innovations Ltd
Publication of BR112023021631A2 publication Critical patent/BR112023021631A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/745—Assays involving non-enzymic blood coagulation factors
    • G01N2333/755—Factors VIII, e.g. factor VIII C [AHF], factor VIII Ag [VWF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Plant Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112023021631A 2021-04-20 2022-04-20 Inibidor, anticorpo ou fragmento de ligação a antígeno, composição farmacêutica, sequência de polinucleotídeo, cassete de expressão, vetor recombinante, célula hospedeira, métodos para preparar o anticorpo ou fragmento de ligação a antígeno e para diagnosticar ou prognosticar uma condição causada pela aglutinação mediada por plaqueta, kit para diagnosticar um indivíduo, e, uso BR112023021631A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2105625.4A GB202105625D0 (en) 2021-04-20 2021-04-20 Von willebrand factor (VWF) inhibitors
PCT/GB2022/050989 WO2022223966A1 (en) 2021-04-20 2022-04-20 Von willebrand factor (vwf) inhibitors

Publications (1)

Publication Number Publication Date
BR112023021631A2 true BR112023021631A2 (pt) 2024-02-27

Family

ID=76377797

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023021631A BR112023021631A2 (pt) 2021-04-20 2022-04-20 Inibidor, anticorpo ou fragmento de ligação a antígeno, composição farmacêutica, sequência de polinucleotídeo, cassete de expressão, vetor recombinante, célula hospedeira, métodos para preparar o anticorpo ou fragmento de ligação a antígeno e para diagnosticar ou prognosticar uma condição causada pela aglutinação mediada por plaqueta, kit para diagnosticar um indivíduo, e, uso

Country Status (12)

Country Link
US (1) US20240228660A1 (https=)
EP (1) EP4326778A1 (https=)
JP (1) JP2024514708A (https=)
KR (1) KR20240004332A (https=)
CN (1) CN117597367A (https=)
AU (1) AU2022262695A1 (https=)
BR (1) BR112023021631A2 (https=)
CA (1) CA3214716A1 (https=)
GB (1) GB202105625D0 (https=)
IL (1) IL307441A (https=)
MX (1) MX2023012391A (https=)
WO (1) WO2022223966A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202215432D0 (en) * 2022-10-19 2022-11-30 Ip2Ipo Innovations Ltd Von Willebrand factor (VWF) antibody

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR070141A1 (es) * 2008-01-23 2010-03-17 Glenmark Pharmaceuticals Sa Anticuerpos humanizados especificos para el factor von willebrand
EP2543678A1 (en) * 2011-07-08 2013-01-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies for the treatment and prevention of thrombosis

Also Published As

Publication number Publication date
JP2024514708A (ja) 2024-04-02
US20240228660A1 (en) 2024-07-11
MX2023012391A (es) 2024-02-02
CN117597367A (zh) 2024-02-23
KR20240004332A (ko) 2024-01-11
IL307441A (en) 2023-12-01
EP4326778A1 (en) 2024-02-28
WO2022223966A1 (en) 2022-10-27
CA3214716A1 (en) 2022-10-27
GB202105625D0 (en) 2021-06-02
AU2022262695A1 (en) 2023-10-05

Similar Documents

Publication Publication Date Title
Paulus et al. Biomarkers of endothelial dysfunction: can they help us deciphering systemic inflammation and sepsis?
Reikvam et al. Thrombelastography
Hellum et al. Microparticle-associated tissue factor activity correlates with plasma levels of bacterial lipopolysaccharides in meningococcal septic shock
Schwameis et al. D-dimer and histamine in early stage bacteremia: a prospective controlled cohort study
Tripodi et al. Antiphospholipid syndrome: laboratory detection, mechanisms of action and treatment
THALER et al. Microparticle‐associated tissue factor activity, venous thromboembolism and mortality in pancreatic, gastric, colorectal and brain cancer patients
Bertolaccini et al. Prevalence of antibodies to prothrombin in solid phase (aPT) and to phosphatidylserine-prothrombin complex (aPS/PT) in patients with and without lupus anticoagulant
US9664695B2 (en) Method for diagnosing or monitoring kidney function or diagnosing kidney dysfunction
BR112023021631A2 (pt) Inibidor, anticorpo ou fragmento de ligação a antígeno, composição farmacêutica, sequência de polinucleotídeo, cassete de expressão, vetor recombinante, célula hospedeira, métodos para preparar o anticorpo ou fragmento de ligação a antígeno e para diagnosticar ou prognosticar uma condição causada pela aglutinação mediada por plaqueta, kit para diagnosticar um indivíduo, e, uso
Yamashita et al. Elevated plasma levels of soluble C-type lectin-like receptor 2 (CLEC2) in patients with thrombotic microangiopathy
Witzel et al. Detection of activated leukocyte cell adhesion molecule in the serum of breast cancer patients and implications for prognosis
AR121388A1 (es) Anticuerpos anti dímero d recombinantes, procedimientos y utilizaciones de los mismos
de Willige et al. The level of circulating fibroblast activation protein correlates with incorporation of alpha-2-antiplasmin into the fibrin clot
Kang et al. Thromboelastography with platelet studies (TEG® with PlateletMapping®) after rattlesnake envenomation in the southwestern United States demonstrates inhibition of ADP-induced platelet activation as well as clot lysis
Vaiyapuri et al. Rhinocetin, a venom-derived integrin-specific antagonist inhibits collagen-induced platelet and endothelial cell functions
Jaskowski et al. Autoantibodies against phosphatidylserine, prothrombin and phosphatidylserine–prothrombin complex: identical or distinct diagnostic tools for antiphospholipid syndrome?
Mackman et al. Challenges with measuring tissue factor antigen and activity in human plasma
Schoppmann et al. Thrombocytes correlate with lymphangiogenesis in human esophageal cancer and mediate growth of lymphatic endothelial cells in vitro
de Vries et al. Levels of fibrinogen variants are altered in severe COVID-19
Ma et al. Preoperative peripheral plasma fibrinogen level is an independent prognostic marker in penile cancer
Kovářová et al. Thyroid-stimulating hormone concentration as an independent risk factor of venous thromboembolism regardless of thyroid function
CN104914256A (zh) 用作体外试验中异常凝血对照血浆的组合物
Devreese et al. Diagnostic test combinations associated with thrombosis in lupus anticoagulant positive patients
AR084886A1 (es) Proteinas de union a inhibidores de factores de coagulacion
Langholm et al. Enhanced processing of von Willebrand factor reflects disease severity and discriminates severe portal hypertension in cirrhosis